Cancer Research UK has enrolled the first 240 patients in its Stratified Medicine Programme, designed to create a multi-gene testing panel for oncology drugs.

It is hoped that the £5.5m programme will aid the development of oncology drugs tailored to differing tumour characteristics, whereas a database of information on targeted cancer therapies will also be compiled.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Supported by both AstraZeneca and Pfizer, the programme plans to test up to 9,000 tumour samples to identify genetic markers in cancers including breast, bowel, lung, prostate, ovarian, and melanoma.

Medical staff from seven Experimental Cancer Medicine Centres across the UK will participate in the programme.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now